| Catalog No. |
Size |
Price |
Figures |
|---|
Z02013-1 mg
| 1 mg | $ 105.00 |
References:
- Kottilil S, et al. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J. Immunol. Jan 2006; 176(2): 1107-1114.
- Barbouche R, et al. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion. J. Biol. Chem. Jan 2003; 278(5): 3131-3136.
|
|---|
| Full Name | | Human Immunodeficiency Virus (HIV) Type O Envelope (synthetic) |
|
| Abbreviated Name-1 | HIV type-O envelope (synthetic) |
|---|
| Description | GenScript Human Immunodeficiency Virus (HIV) Type O Envelope (synthetic), containing the HIV type-O transmembrane envelope-derived specific sequence. Detects all clades of HIV type-O infected individuals responding to HIV-type O envelope proteins. |
|---|
| Purity | Peptide is >95% pure As determined by HPLC-C18, and MASS Analysis. |
|---|
| Storage | Reagent is shipped at ambient temperature. Freeze upon arrival. Store at -20°C. |
|---|
| Concentration | 1 mg/ml in H2O. |
|---|
| Stability | Five years frozen. One month in solution at 4°C. |
|---|
| Specificity | Immunoreactive with all sera of HIV type-O infected individuals. |
|---|
| Applications | Antigen in Rapid Tests, ELISA and Western blots. |
|---|
